Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 14 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11286291

    Co-stimulatory domains for use in genetically-modified cells

    Precision BioSciences, Inc. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted

  2. US 11278535

    Compounds and their methods of use

    PRAXIS PRECISION MEDICINES, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  3. US 11278529

    Methods for treating aggression associated with Alzheimer's disease

    OVID THERAPEUTICS INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  4. US 11279768

    Anti-cancer antibodies, combination therapies, and uses thereof

    PRECISION BIOLOGICS, INC. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  5. US 11278632

    Engineered nucleases useful for treatment of hemophilia A

    Precision BioSciences, Inc. · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  6. US 11278572

    Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 22, 2022 · Expires Mar 17, 2042

    granted

  7. US 11274305

    Compositions and methods for in vivo excision of HIV-1 proviral DNA

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  8. US 11274285

    Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome

    Precision BioSciences, Inc. · Granted Mar 15, 2022 · Expires Mar 10, 2042

    granted

  9. US 11266693

    Nucleic acids encoding engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  10. US 11268065

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  11. US 11268096

    Compounds for modulating Fc-epsilon-RI-beta expression and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  12. US 11267845

    Inhibitors of CD73-mediated immunosuppression

    Arcus Biosciences, Inc. · Granted Mar 8, 2022 · Expires Mar 3, 2042

    granted

  13. US 11261188

    Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel

    PRAXIS PRECISION MEDICINES, INC. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  14. US 11260050

    Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological

    United States Government as represented by the Department of Veterans Affairs · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  15. US 11260120

    Immunogenic composition comprising a fusion peptide derived from superantigen toxoids

    INTEGRATED BIOTHERAPEUTIC VACCINES, INC. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  16. US 11261447

    Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Mar 1, 2022 · Expires Feb 24, 2042

    granted

  17. US 11254725

    Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  18. US 11254731

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted

  19. US 11248039

    Immunoglobulin single variable domain antibody against RSV prefusion F protein

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted

  20. US 11241451

    Modulators of IRF4 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 8, 2022 · Expires Feb 3, 2042

    granted

  21. WO 2022025781

    DISPERSION SOLIDE D'OPICAPONE

    BIAL PORTELA & Cª S A [PT] · Granted Feb 3, 2022 · Expires Jan 29, 2042

    granted

  22. US 11236315

    Thermophile peptidoglycan hydrolase fusion proteins and uses thereof

    The United States of America, as represented by the Secretary of Agriculture · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  23. US 11236339

    Modulation of GYS1 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

  24. US 11236338

    Antisense-induced exon2 inclusion in acid alpha-glucosidase

    Sarepta Therapeutics, Inc. · Granted Feb 1, 2022 · Expires Jan 27, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.